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Abstract
The National Institute for Occupational Safety and Health is conducting research on the effects
of respiratory exposure to carbon nanotubes. Exposure to some kinds of carbon nanotubes has
been associated with a fibrogenic response in lungs that has negative effects on lung physiology and human health. A thorough understanding of the molecular events leading to fibrosis
could offer prophylactic or therapeutic approaches to avoid the fibrosis. Several different enzymes are associated with fiber formation in the lung ,and one of interest is prolyl hydroxylase
(PH-4). Current protocols for measuring PH-4 activity are expensive, cumbersome, and timeconsuming. A rapid assay protocol would aid in our understanding of the regulation on the enzyme’s activity. To prepare the tissue for assay, it was homogenized and then microsomes were
prepared by differential centrifugation. Then, a surfactant was used to solubilize the protein,
allowing substrate access. The incubation occurred in stoppered vials. The vials were placed in
a 37 degree C water bath with shaking. A radioactive co-substrate for the reaction, 2-oxo[1-14C]glutarate, was incubated in the presence and absence of a synthetic peptide containing proline
and the liberated 14CO2 was captured. The reaction was terminated by adding pH 5 phosphate
buffer to the reaction vial. Radioactivity was determined using liquid scintillation spectrometry.
The peptide-dependent 14CO2 captured was used to estimate enzyme activity. This assay has
been determined to be linear with respect to enzyme concentration as well as incubation time.
This is a useful method as it can be completed in a matter of hours and requires no previous
preparation of tissue or substrate. This rapid assay will be used to assess PH-4 in mouse lung
from mice exposed or not exposed to carbon nanotubes. PH-4 regulation, or a lack thereof, after
nanotube exposure suggests the molecular pathway by which the fibrogenic response associated with carbon nanotube exposure is elicited.
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Introduction

Carbon nanotubes are cylindrical carbon molecules with diameters on the order of nanometers
and lengths on the order of micrometers (Chen et al. 2000). Carbon nanotubes are important
because they have several novel and potentially useful properties making them desirable for
many industrial and commercial applications. The manufacture of carbon nanotubes is increasing, and as such they are coming under increased toxicological scrutiny (Donaldson et al. 2006).
Because of their size and physical properties, it is suspected that the toxicity of carbon nanotubes
may be similar to that of asbestos (Prosie et al. 2008). Part of the physiological response elicited
by asbestos fiber exposure is collagen deposition in the lung tissue (Wrzaszczyk and Owczarek
1996). PH-4 is an enzyme necessary for the production of collagen. It is a 2-oxoglutarate dioxygenase and catalyzes the reaction:
procollagen L-proline + 2-oxoglutarate + O2 n procollagen trans-4-hydroxy-L-proline + succinate + CO2 (Brenda enzyme database)
The enzyme decarboxylates 2-oxoglutarate. Also, one oxygen atom from the O2 becomes
incorporated into the succinate while the other oxygen atom from the O2 becomes incorporated
into the proline to generate 4-hydroxyproline. The enzyme is necessary for collagen production
because the hydroxyl groups on the 4-hydroxyprolyl residues stabilize the triple helix of collagen under physiological conditions. The enzyme cannot interact with free proline or with proline occurring in just any amino acid sequence. Rather, it requires a minimum X-Pro-Gly triplet
to interact with the proline. The intracellular location of PH-4 is within the cisternae of the rough
endoplasmic reticulum. The enzyme requires Fe2+ and ascorbate, and maximal enzyme activity
requires dithiothreitol, bovine serum albumin, and catalase (Kivirikko and Myllylo 1982).
The National Institute for Occupational Safety and Health (NIOSH) is currently conducting research on the effects of respiratory exposure to carbon nanotubes. Early results have demonstrated that some kinds of carbon nanotubes do elicit a fibrogenic response that leads to health
problems (Lam et al. 2006; Shvedova et al. 2005). NIOSH is interested in determining the molecular pathway by which this fibrogenic response occurs. A change in the regulation of PH-4, or
a lack thereof, after nanotube exposure suggests the molecular pathway by which the fibrogenic
response occurs. For example, if PH-4 is upregulated it may indicate collagen deposition and
thus a fibrogenic pathway similar to that of asbestos. Our role in NIOSH’s larger study will be to
determine if PH-4 regulation is altered in mouse lung after carbon nanotube exposure.
Several assays have been developed to measure the activity of PH-4. The assays use either
radiolabeled biologically prepared substrate or a synthetic polypeptide substrate (as the source
of procollagen-L-proline). The assays involving radiolabeled biologically prepared substrates
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are the most sensitive, and in most reported cases only these methods can be used to accurately
determine enzyme activity from crude tissue extracts (Kivirikko and Myllylo 1982). Unfortunately, these assays are expensive, cumbersome, and time-consuming. The assays using synthetic polypeptide substrates are less expensive and faster, but they have lower sensitivity and
in most cases can only be used with partially purified enzyme.
For this particular project a quick, inexpensive assay that could be used with crude tissue
extract was desired. By adapting previously published results (Kao et al. 1975; Kivirikko and
Myllylo 1982), such an assay has been developed, and it will allow us to determine whether
PH-4 regulation is altered after carbon nanotube exposure.

Methods and Calculations
Assay Overview
The components necessary to carry out the reaction (enzyme extract, peptide substrate, labeled
2-oxoglutarate, and cofactors) were added to a 3 mL reaction vial. The labeled 2-oxoglutarate
was added last to begin the reaction. The reaction vial was then incubated at 37 degree C for 20
minutes. The reaction was ended by injecting pH 5 phosphate buffer into the reaction vial. The
reaction vial was then shaken for 30 minutes to release the evolved CO2. A base trap suspended
in the reaction vial collected the evolved CO2. This base trap was then placed in a liquid scintillation vial and counted.

Preparation of Assay Components
Crude enzyme extract was obtained from mouse lung. After the mice were sacrificed, their lungs
were immediately harvested, weighed, and homogenized in enzyme buffer (Kao et al. 1975) (.2
M NaCl, .1 M glycine, 50µM DTT, .01M Tris-HCl, pH 7.8) using a Potter-Elvehjem tissue grinder
and approximately 1mL buffer per gram of tissue. Depending on the particular experiment being done, between 1 and 5 mice were used. When multiple mice were used, their homogenized
lungs were combined into one homogenate. The homogenate was then centrifuged in 1.5mL
Eppendorf tubes at 10,000 x g for 20 minutes. The supernatant was then collected and put on
ice. The pellet was resuspended in .5mL NaCl buffer and again centrifuged at 10,000 x g for 20
minutes. This supernatant was collected and added to the previously collected supernatant. The
combined supernatant was then centrifuged at 37,000 x g for 30 minutes. The resulting pellet
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was then collected (representing the microsomal fraction) and resuspended in the NaCl buffer.
Triton X-100 (0.1 %) was added and the solution was placed on ice.
While centrifuging the enzyme extract, a “Master Mix” of enzyme cofactors and activators was prepared and kept on ice. This “Master Mix” consisted of 20mM ascorbic acid, 1mM
FeSO4, 1mM DTT, 20mg/mL bovine serum albumin, and 2 mg/mL catalase (Kivirikko and Myllylo 1982). The amount of Master Mix prepared was determined by the number of trials to be run
(.333mL/trial).
The peptide substrate (Pro-Pro-Gly)10 • 9 H2O was diluted to 1 mg/mL in distilled water
and then heated at 100 degrees C for 10 minutes. After heating, the peptide was placed on ice.
The amount of peptide prepared was determined by the number of trials to be run (.1mL/trial).
A solution of 2mM 2-oxoglutarate was prepared. The amount of 2-oxoglutarate prepared
was determined by the number of trials to be run (.05mL/trial). Additionally, 20µL of 2-oxo-[1C]glutarate (56.8mCi/mmol) was added to the 2-oxoglutarate solution. This solution was then
placed on ice.
14

Trial Preparation
The reaction was carried out in 3 mL vials. These vials were kept on ice
as the assay components were added. A 5mm boiling bead was placed
in each reaction vial. Master Mix (.333mL) and enzyme extract (.3mL)
were added to each reaction vial.
A base trap was prepared to capture the evolved CO2. The base
trap consisted of methyl cellusolve and ethanolamine in a 2:1 ratio.
Base trap (.45mL) was added to a .5mL Eppendorf tube that was then
suspended inside of the reaction vial.
Peptide solution (.1mL) was added to each treatment vial and
(.1mL) distilled H2O was added to each control vial.

Figure 1

In Figure 1, the 3mL reaction vial with .5mL Eppendorf tube suspended from the stopper.
The Master Mix, 2-oxoglutarate, and peptide substrate are injected into the bottom of the reaction vial. The base trap is placed in the Eppendorf tube and collects the evolved CO2.
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Assay

Labeled 2-oxoglutarate (.05mL) was then added to each vial to start the reaction. Each vial was
then immediately stoppered with the base trap suspended from a wire attached to the stopper.
The vials were then incubated at 37 degrees C with shaking for 20 minutes. The reaction was
ended in each vial by adding .5mL of pH 5 phosphate buffer (1 M KH2PO4) via a syringe inserted
through the stopper.
The vials were then taken out of the water bath and shaken for 30 minutes at room temperature.
The Eppendorf tube containing the base trap was then added to a counting vial along
with a scintillation cocktail and counted.

Calculation of Enzyme Activity
From the scintillation spectrometer we get a DPM (disintegrations per minute) value representing the labeled CO2 collected in the base trap. This DPM value is converted to a CO2 (and thus
an enzyme activity) level by comparing it to the DPM from a labeled 2-oxoglutarate solution of
known concentration. For enzyme specific activity, the DPM difference between the treatment
trials and the control trials is used.
The calculation for enzyme specific activity is then:
(Treatment DPM – Control DPM) * ((moles 2-oxoglutarate)/(2-oxoglutarate vial counts)) =
moles labeled CO2
This result is divided by the amount of mouse tissue in each sample to get a unit for enzyme
activity that has units of moles CO2 evolved/g mouse tissue.
To optimize the assay in various respects the experiments shown below in table 1, table
2, and table 3 were performed. These experiments optimized the Master Mix volume, the size of
the reaction vessel, and the rate of shaking during incubation. In each of these experiments, the
procedure used was very close to the one just described.
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Results

For all experimental results, the raw data came in the form of Disintegrations Per Minute (DPM).
Enzyme specific DPM was obtained by taking the difference between trials run with the enzyme’s
peptide substrate ((Pro-Pro-Gly)10 • 9 H2O) and trials run without it. This enzyme specific DPM
can then be converted to enzyme activity with units of moles CO2 evolved per gram tissue.
Table 4 and Figure 2 demonstrate the linearity of our assay with respect to differing enzyme concentration. Table 5 and Figure 3 demonstrate the linearity of our assay with respect to
time.
Table 1 :Effect of Variations in Master Mix Volume
Master Mix .1666 mL
Volume
peptide
1154.23
1023.34
678.87
1409.23
899.45
1890.21
1722.39
1300.23
Average
1259.74375
Enzyme
258.4725
specific
DPM
Standard
408.789206
Deviation
T-Test
0.194224355

.1666 mL no
peptide
1011.11
645.6
659.12
605.72
1432.3
1222.9
983.34
1450.08
1001.27125

.333 mL
peptide
1358.28
1221.34
1477.24
1332.98
1003.32
1060.43
1232.21
1278.33
1245.51625
320.485

.333 mL no
peptide
564.5
1051.12
908.43
1013.13
1066
998.08
955.65
843.34
925.03125

.5 mL peptide
654.09
1768.8
1245.56
1521.23
1165.34
432.23
976.45
1343.75
1138.43125
143.3475

.5 mL no
peptide
987.65
795.26
1654.23
1256.67
1340.48
543.7
923.21
459.47
995.08375

345.7461947 155.2949729 163.3302627 440.4219828 406.7255518
0.00126636

0.509929937

This experiment was done using the 3mL reaction vial and shaking 110r/min. The Master
Mix volume used in Kao et al. (1975) is .5mL. In this project smaller amounts of tissue are used,
so it was decided to concentrate the Master Mix in an attempt to lower the reaction volume and
obtain more precise results. The above data shows that lowering the Master Mix volume to
.333mL increases the precision of the assay over the precision achieved when using Master Mix
volume .5mL or .1666mL.
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Table 2: Effect of Changing The Size of The Reaction Vessel
#(New) 3 mL reaction
vial peptide
539.6
625.6
635.7
541.7
411.4
604.9
401.7
622.5
446.6
584.2

(New) 3 mL reaction
vial no peptide
343.6
383.5
349.1
358.1
443.6
445.1
348.4
377.7
331.7
354.1

(Original) 25 mL Erlenmeyer peptide
358.4
542.8
486.4
677.9
827.5
482.3
664.4
861.4
709.3
456.67

(Original) 25 mL Erlenmeyer no peptide
187.4
333.2
535
301.2
491.9
565.1
558.2
866.1
543.1

average
average
541.39
373.49
standard deviation
90.57218668
40.32968165
Enzyme Specific DPM
167.9
ttest new
0.000152392

average
606.707

average
486.8

Coefficient of variance
16.72956403

Coefficient of variance
27.5114797

Coefficient of variance
10.79806197

166.9140732
196.3087364
Enzyme Specific DPM
119.907
ttest old
0.173208502
Coefficient of variance
40.32636328

This experiment was done using .5mL Master Mix and shaking 110r/min. Once again,
due to the small amounts of tissue being used in this project, it was decided to lower the volume
of the reaction vessel to try to cause more efficient mixing of the assay components and thus increase the precision of the assay. The above data shows that lowering the volume of the reaction
vessel (from 25mL to 3mL) does increase the precision of the assay.

murr 1.1					
					

53

Table 3: Effect of Changing the Rate of Shaking During Incubation
shaking
50 peptide
rate (r/ min)
1065.3
1034.9
876.54
665.2
1209.92
1250

50 no peptide
934.21
854.06
1260.75
565.4
875.2
920.43

80 peptide
1078.12
855.5
980.1
1184.46
1353.3
1109.23

80 no peptide
956.65
1190.22
860.98
544.4
990.02
1105.5

110 peptide 110 no peptide
1240.1
954.23
1168.89
904.45
1300.4
654.15
988.89
1023.2
1002.24
838.26
1037.72
906.5

Average

1016.976667 901.675

1093.451667 941.295

1123.04

Enzyme
Specific
DPM

115.3016667

152.1566667

242.9083333

Standard
Deviation

218.0149879 221.9883426 170.7379775 226.0588329 132.0077275 126.5438513

T-test

0.385384722

0.219793911

880.1316667

0.008684604

This experiment was done using the 25mL Erlenmeyer flask and .5mL Master Mix. Increasing the rate of shaking during incubation more thoroughly mixes the assay components
and increases the precision of the assay. Also, the enzyme specific DPM appears to increase with
faster shaking. This is an added benefit, as higher enzyme specific DPM will make it easier to
identify differences in enzyme specific DPM between individual mice.
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Table 4: DPM With and Without Peptide Substrate and at Differing Enzyme Concentration
[1] peptide
1518.03
2403.81
1355.81
1211.08
1535.73
952.4

[1] no peptide
871.9
776.8
781.3
930
839.3
1048.69

[.5] peptide [.5] no peptide
733.1
431.4
607.6
524.9
641
376.9
247.1
265.9
878.5
402.7
551.1
184.8

[.25] peptide
405.8
332.4
410.8
500.3
385
374.1

average
Enzyme
Specific
DPM
t-test

1496.143333 874.665
621.4783333

609.7333333 364.4333333 401.4
245.3
48.18

0.026679563

0.039117194

standard
deviation

494.4727028 102.8587116 211.3659449 121.516084

[.25] no
peptide
374.7
350.3
376.6
306.2
358.3

353.22

0.104464231
55.97174287 28.51853783

In this experiment, the assay was performed at standard enzyme concentration (represented by [1]) and also at one-half and one-fourth normal enzyme concentration ([.5] and [.25]).
The t-tests compare the trials with the peptide substrate added for a given enzyme concentration
to the trials without the peptide substrate added for that enzyme concentration.
In Figure 2: Graphical representation of the data
from Table 4. Here the difference in DPM between Treatments (peptide) and Controls (no peptide) has been
converted to enzyme activity
with units of nanomoles CO2
evolved per minute.

Figure 2
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Table 5: DPM With and Without Peptide Substrate and with Respect to Time
5 minutes
peptide
706.2
668.3
597.4
670.1
747.8

5 minutes
no peptide
348.4
289.6
193.1
406.65
355.56

20 minutes
peptide
2087.89
2190.91
2066.19
1789.29
1983.23

20 minutes
no peptide
1512.58
1775.27
1422.98
1418.44
1467.04

60 minutes
peptide
2780.51
3155
3681.09
2580.77
2637.9

60 minutes
no peptide
1557.67
1985.94
1886.92
2325.58
2229.12

1519.262

2967.054
1997.046
0.005486779

Average
T-test

677.96
318.662
0.003374733

2023.502
0.13618652

Enzyme
specific
DPM
Standard
Deviation

359.298

504.24

55.49804501 81.5446425

150.3916664 148.1107539 457.5826309 302.9419413

970.008

In this experiment the reaction was allowed to run for 5, 20, or 60 minutes.
Figure 3 is a Graphical
representation of the data from
Table 5. Here the difference
in DPM between Treatments
(peptide) and Controls (no
peptide) has been converted
to enzyme activity with units
of nanomoles CO2 evolved per
gram of lung.

Discussion
Figure 3
The assay developed here
is based on previously published results (Kao et al. 1975; Kivirikko and Myllylo 1982). In previous studies, researchers
were concerned with demonstrating that a PH-4 assay that measures enzyme activity by following the release of 14CO2 is reliable. In developing a PH-4 assay for use in the NIOSH project we
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had the added requirement that the assay be able to be used to determine whether or not a statistical difference exists between the PH-4 activities of the lungs of individual mice. This meant
that the assay needed to be able to give reliable enzyme activities using small amounts of tissue
(a single mouse lung weighs ~.1g). In previously reported results working with small amounts
of tissue was not a concern. For example, in Kao et al. (1975) 5g of tissue would typically be used
per assay (the 5g value came from combining tissue from many subjects).
Having to work with a small amount of tissue means a couple things. Obviously, less
tissue means less enzyme and thus less activity for us to measure. At low levels of activity it becomes difficult to obtain a statistically significant result. Further, because there is some inherent
variability in the DPM for any given trial using this assay (note the large standard deviations in
the Results section) it is necessary to run several treatment and control trials to get a sufficiently
precise measurement of enzyme activity. Thus, our problem was that we needed to find a way to
run several trials that produced DPM numbers high enough to be of use using a small amount
of tissue.
The first step taken in this direction was to add an additional round of centrifugation at
10,000 x g in order to retain more of the microsomal fraction (PH-4’s subcellular location is the
endoplasmic reticulum). By next centrifuging the resulting supernatant at 37,000 x g and taking
the pellet, the microsomal and mitochondrial fractions were separated. This is a useful step as
2-oxoglutarate is also a substrate for the oxoglutarate dehydrogenase complex of the citric acid
cycle which occurs in the mitochondria. The result of this separation is that a larger percentage
of the total activity during the incubation period is enzyme specific.
The surfactant Triton X-100 is used to solubilize PH-4 and allow it access to its peptide
substrate. Rather than include the surfactant in the homogenization buffer as is done in the literature, we elected to add the surfactant after the microsomal fraction is collected. Adding the
surfactant at this time reduces the chance that unwanted enzymes that will interfere with data
collection will also be solubilized.
These changes in the centrifuging and solubilization procedure were necessary to obtain
enzyme specific activity. That is, the difference between treatment and control trials was statistically insignificant before making these changes to the assay.
Again due to the small amount of tissue being used, we elected to further alter the assay
as described in the literature by using a smaller amount of Master Mix solution, carrying out the
reaction in a smaller vessel, and shaking the reaction vials more vigorously during incubation.
The benefit of these changes is shown in Tables 1, 2, and 3, respectively. Using .333mL as the volume for the Master Mix resulted in the highest enzyme specific DPM and the lowest standard
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deviation. The .333mL Master Mix also returned the lowest T-test result. Using the 3mL reaction
vial instead of the 25mL Erlenmeyer flask to carry out the reaction lowered the standard deviation and returned a lower T-test value. Finally, shaking the reaction vial more vigorously during
incubation (110r/min as opposed to 80 or 50) lowered the standard deviation and returned a
lower T-test value.
This assay has been demonstrated to be linear with respect to both enzyme concentration
(Table 4, Fig. 2) and time (Table 5, Fig. 3). These results are important as they demonstrate that
the assay gives results that fit basic biochemical theory.
The assay is quick, easy, and inexpensive. It requires no previous preparation of tissue or
substrate and can be completed from start to finish in a little over 5 hours. Reliable results have
also been obtained breaking up the assay into two parts. After the last centrifugation step the
enzyme extract can be placed on ice overnight and used the next day. This makes the assay even
more convenient, as it creates two approximately three hour work sessions.
After much troubleshooting and tweaking, the assay is now at a point where it can be
used for its intended purpose, determining whether or not carbon nanotube exposure alters
PH-4 regulation in mouse lung.
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